|
1
|
Targeting abnormal DNA repair in therapy-resistant breast cancers.
|
Mol Cancer Res
|
2011
|
1.07
|
|
2
|
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.93
|
|
3
|
Challenges in the endocrine management of breast cancer.
|
Breast
|
2003
|
0.92
|
|
4
|
Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.
|
J Steroid Biochem Mol Biol
|
2012
|
0.88
|
|
5
|
HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
|
Mol Cancer Ther
|
2013
|
0.85
|
|
6
|
Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB.
|
Mol Cancer Ther
|
2013
|
0.81
|
|
7
|
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
|
Breast Cancer Res
|
2014
|
0.79
|